ALXN - アレクション・ファ―マシュ―ティカルズ (Alexion Pharmaceuticals Inc.) アレクション・ファ―マシュ―ティカルズ

 ALXNのチャート


 ALXNの企業情報

symbol ALXN
会社名 Alexion Pharmaceuticals Inc. (アレクション・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アレクシオン・ファーマシューティカル(Alexion Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は治療薬の開発と商品化に集中する。同社の製品はソリリス(エクリズマブ)、Strensiq(アスファターゼアルファ)およびカヌマ(セベリパーゼアルファ)などを含む。同社の臨床開発プログラムはソリリス(エクリズマブ)、cPMP(ALXN1101)、SBC-103、ALXN1210(IV)およびALXN1210(皮下)などを含む。同社のソリリスは発作性夜間ヘモグロビン尿症(PNH)と溶血性尿毒症症候群(aHUS)患者向けの承認された治療薬である。PNHとaHUSは免疫システムの補完成分の慢性的な制御不能な活性化に起因した。同社のStrensiqは低ホスファターゼ患者向けの治療薬である。同社の製品Kanumaはリソソーム酸リパーゼ欠損症(LAL-D)患者向けの治療薬である。KanumaはヒトLAL酵素の組換え型であり、LAL-D患者の治療用補充療法である。   アレクション・ファ―マシュ―ティカルズはバイオ医薬品の世界大手。主な医薬品に発作性夜間血色素尿症と非定型溶血性尿毒症の治療薬ソリリス「Soliris」を開発。また、遺伝性血液障害に対する医薬品も開発。各種の臨床プログラムや、臨床試験のための酵素補充療法も提供。本社は米国コネチカット州。   
本社所在地 121 Seaport Boulevard Boston MA 02210 USA
代表者氏名 David R. Brennan デヴィッド・R・ブレナン
代表者役職名 independent Chairman of the Board
電話番号 +1 475-230-2596
設立年月日 33604
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 2525人
url www.alexion.com
nasdaq_url https://www.nasdaq.com/symbol/alxn
adr_tso
EBITDA EBITDA(百万ドル) 1451.8
終値(lastsale) 129.46
時価総額(marketcap) 28851345300.08
時価総額 時価総額(百万ドル) 29100.95
売上高 売上高(百万ドル) 3745
企業価値(EV) 企業価値(EV)(百万ドル) 31128.75
当期純利益 当期純利益(百万ドル) -15.80000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alexion Pharmaceuticals Inc. revenues increased 11% to $1.98B. Net loss before extraordinary items totaled $169.9M vs. income of $335M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Selling/General/Admin. Expense increase of 31% to $278.6M (expense).

 ALXNのテクニカル分析


 ALXNのニュース

   Alexion Pharmaceuticals (NASDAQ:ALXN) Releases Earnings Results, Beats Estimates By $0.40 EPS  2021/02/05 21:28:41 Transcript Daily
Alexion Pharmaceuticals (NASDAQ:ALXN) released its earnings results on Wednesday. The biopharmaceutical company reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.56 by $0.40, MarketWatch Earnings reports. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.51 billion. Alexion Pharmaceuticals had a return on equity of 23.16% […]
   Alexion Pharmaceuticals (ALXN) Set to Announce Earnings on Thursday  2021/02/03 08:34:44 Transcript Daily
Alexion Pharmaceuticals (NASDAQ:ALXN) will be posting its quarterly earnings results before the market opens on Thursday, February 4th. Analysts expect Alexion Pharmaceuticals to post earnings of $2.25 per share for the quarter. NASDAQ:ALXN opened at $154.86 on Wednesday. Alexion Pharmaceuticals has a 1-year low of $72.67 and a 1-year high of $162.60. The company has […]
   Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders Are Encouraged to Contact the Firm - RP, OXFD, FFG, MDCA, ALXN, CHNG  2021/01/30 22:03:00 PR Newswire
NEW YORK, Jan. 30, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: RealPage, Inc. (NASDAQ: RP) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its…
   SHAREHOLDER ALERT: WeissLaw LLP Reminds THBR, GIX, ALXN and STPK Shareholders About Its Ongoing Investigations  2021/01/29 21:26:00 PR Newswire
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor…
   Chief Diversity Officers Take On New Visibility, Challenges  2021/01/27 19:25:48 Benzinga
JLL (NYSE: JLL ), the Chicago-headquartered commercial real estate services company, announced the appointment this week of Ingrid Jacobs to the newly created global role of head of diversity and inclusion. Why It's Important: JLL is the latest publicly traded company to add diversity officer positions into their senior executive hierarchy. In recent months, chief diversity officer positions were established at CBRE (NYSE: CBRE ), XPO Logistics (NYSE: XPO ), National Grid (NYSE: NGG ), Cadence Bancorp (NYSE: CADE ), Aramark (NYSE: ARMK ), Alexion (NASDAQ: ALXN ) and Cushman & Wakefield (NYSE: CWK ). The concept of a chief diversity officer is not new: the position can be traced back to academia in the 1970s, when colleges and universities began to establish "minority affairs" positions in response to the rising number of nonwhite students. In the private sector, the issue of bringing greater diversity within the workforce, the C-Suite and the board room has percolated for years without dramatic change.
   Alexion’s long-term prospects remain intact amid continued focus on rare diseases  2020/12/02 18:19:41 AlphaStreet
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has stood out in the crowded pharmaceuticals marketplace by developing effective treatments for certain rare health conditions. The strategy is expected to come in handy for […]
   Global Pancreatic Enzyme Replacement Therapy Market To Reflect Impressive Growth Rate by 2027 ||Shire Plc; Sanofi S.A., Biomarin Pharmaceutical Inc., AbbVie Inc, Alexion Pharmaceuticals Inc., Allergan plc, Horizon Pharma Public Limited Company  2020/11/27 13:27:03 OpenPR
Data Bridge Market Research has provides the Qualitative and informative knowledge by adding titled “Global Pancreatic Enzyme Replacement Therapy Market, By Type (Enteric Coated and Non-Enteric Coated), Treatment (Medication, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics,
   Alexion Pharmaceuticals (NASDAQ:ALXN) Now Covered by Analysts at Sanford C. Bernstein  2020/11/20 13:04:43 Transcript Daily
Sanford C. Bernstein started coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report released on Thursday, The Fly reports. The firm issued a market perform rating and a $148.00 target price on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on ALXN. Stifel Nicolaus lowered their target price on shares […]
   Alexion Is Reaching New Heights  2020/11/12 17:00:00 The Street RealMoney
Alexion Pharmaceuticals Is Reaching New Heights…ALXN
   Alexion Pharmaceuticals, Inc. Just Recorded A 29% EPS Beat: Here's What Analysts Are Forecasting Next  2020/11/01 12:11:24 Yahoo Finance
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) just released its quarterly report and things are looking bullish. Alexion…
   Alexion Pharmaceuticals, Inc. Just Recorded A 29% EPS Beat: Here's What Analysts Are Forecasting Next  2020/11/01 12:11:24 Yahoo Finance
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) just released its quarterly report and things are looking bullish. Alexion…
   Earnings Scheduled For October 29, 2020  2020/10/29 08:08:21 Benzinga
Companies Reporting Before The Bell • PG&E (NYSE: PCG ) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion. • Silicom (NASDAQ: SILC ) is estimated to report quarterly earnings at $0.35 per share on revenue of $26.68 million. • Ambev (NYSE: ABEV ) is expected to report quarterly earnings at $0.02 per share on revenue of $2.28 billion. • Ares Commercial Real (NYSE: ACRE ) is estimated to report quarterly earnings at $0.24 per share on revenue of $17.15 million. • Alliance Data Systems (NYSE: ADS ) is expected to report quarterly earnings at $2.20 per share on revenue of $1.01 billion. • Agenus (NASDAQ: AGEN ) is expected to report quarterly loss at $0.26 per share on revenue of $14.00 million. • Alexion Pharmaceuticals (NASDAQ: ALXN ) is projected to report quarterly earnings at $2.58 per share on revenue of $1.42 billion. • AMETEK (NYSE: AME ) is estimated to report quarterly earnings at $0.93 per share on revenue of $1.11 billion. • Amerant Bancorp (NASDAQ: AMTB ) is projected to report quarterly earnings at $0.
   Head to Head Analysis: Alexion Pharmaceuticals (NASDAQ:ALXN) & Ironwood Pharmaceuticals (NASDAQ:IRWD)  2020/10/25 04:13:03 US Banking News
Alexion Pharmaceuticals (NASDAQ:ALXN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership. Volatility and Risk Alexion Pharmaceuticals has a beta of 1.35, suggesting that its stock price is […]
   Q3 2020 EPS Estimates for Alexion Pharmaceuticals, Inc. Raised by Analyst (NASDAQ:ALXN)  2020/10/24 06:02:48 Zolmax News
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Stock analysts at SVB Leerink boosted their Q3 2020 EPS estimates for shares of Alexion Pharmaceuticals in a research report issued on Wednesday, October 21st. SVB Leerink analyst G. Porges now expects that the biopharmaceutical company will post earnings of $2.51 per share for the quarter, up from their previous […]
   Alexion Pharmaceuticals, Inc. Expected to Earn Q3 2020 Earnings of $2.33 Per Share (NASDAQ:ALXN)  2020/10/23 06:26:44 Dakota Financial News
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Investment analysts at Wedbush reduced their Q3 2020 earnings per share (EPS) estimates for shares of Alexion Pharmaceuticals in a report released on Monday, October 19th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn $2.33 per share for the quarter, down from their previous forecast of […]

 関連キーワード  (医薬品 米国株 アレクション・ファ―マシュ―ティカルズ ALXN Alexion Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)